Valuation: Novo Nordisk A/S

Market Cap 1,463B 224B 196B 181B 166B 315B 21,542B 320B 2,156B 846B 10,529B 841B 822B 36,291B P/E 2026 *
14.5x
P/E 2027 * 15.6x
Enterprise Value 1,590B 243B 213B 196B 180B 342B 23,414B 348B 2,343B 919B 11,444B 914B 894B 39,445B EV / Sales 2026 *
5.42x
EV / Sales 2027 * 5.29x
Free-Float
71.32%
Yield 2026 *
3.43%
Yield 2027 * 3.34%

Last Transcript: Novo Nordisk A/S

1 day+3.39%
1 week+2.29%
Current month+5.07%
1 month+15.74%
3 months+31.25%
6 months-9.49%
Current year+1.63%
1 week 315.6
Extreme 315.6
331.25
1 month 277.2
Extreme 277.2
332.65
Current year 224.25
Extreme 224.25
409.95
1 year 224.25
Extreme 224.25
464.6
3 years 224.25
Extreme 224.25
1,033.2
5 years 224.25
Extreme 224.25
1,033.2
10 years 109.1
Extreme 109.1
1,033.2
Manager TitleAgeSince
Chief Executive Officer 56 07/08/2025
Director of Finance/CFO 55 15/02/2018
Chief Tech/Sci/R&D Officer - 05/11/2025
Director TitleAgeSince
Director/Board Member 61 23/03/2017
Director/Board Member 51 22/03/2018
Director/Board Member 61 24/03/2022
Date Insider Type Main position Quantity % Market Cap.
11-18Buy

Director

6,450 0.0002%
11-18Sell 8,160 0.0002%
11-18Others 18,634 0.0005%
Change 5-day change 1-year change 3-year change Capi.($)
+3.39%+2.29%-23.68%-37.83% 217B
+0.35%-4.87%+49.87%+157.34% 1,028B
-2.69%-6.22%+59.19%+54.51% 611B
+0.44%-3.41%+30.97%+79.48% 432B
+0.98%-1.40%+29.49%+21.76% 323B
-0.34%-3.10%+27.00%+43.60% 277B
+1.63%-11.76%+19.72%+21.72% 257B
+0.86%-2.63%+22.50%+57.55% 192B
+1.28%-3.03%+20.76%+70.62% 161B
+2.35%+3.20%+0.85%-31.66% 138B
Average +0.81%-3.82%+23.67%+43.71% 363.65B
Weighted average by Cap. +0.26%-4.54%+34.53%+72.58%

Financials

2026 *2027 *
Net sales 293B 44.89B 39.25B 36.21B 33.28B 63.06B 4,320B 64.14B 432B 170B 2,111B 169B 165B 7,277B 300B 45.94B 40.17B 37.05B 34.06B 64.54B 4,421B 65.64B 442B 174B 2,161B 173B 169B 7,447B
Net income 99.54B 15.23B 13.32B 12.29B 11.29B 21.4B 1,466B 21.76B 147B 57.55B 716B 57.2B 55.95B 2,469B 94.05B 14.39B 12.58B 11.61B 10.67B 20.22B 1,385B 20.56B 139B 54.38B 677B 54.05B 52.87B 2,333B
Net Debt 127B 19.45B 17.01B 15.69B 14.42B 27.33B 1,872B 27.79B 187B 73.49B 915B 73.05B 71.45B 3,153B 126B 19.3B 16.88B 15.57B 14.31B 27.12B 1,857B 27.58B 186B 72.92B 908B 72.49B 70.9B 3,129B
Logo Novo Nordisk A/S
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (93.7%); - rare disease treatment products (6.3%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe and Canada (21.4%), the United States (56%), Latin America/Middle East/Africa (9.9%), China/Hong Kong/Taiwan (6%), Asia/Pacific (6.7%).
Employees
67,900
Date Price Change Volume
15/07/26 DKK 330.55 +3.39% 3,793,013
14/07/26 DKK 319.70 -1.45% 2,522,776
13/07/26 DKK 324.40 +0.67% 2,304,422
10/07/26 DKK 322.25 +0.66% 2,598,903
09/07/26 DKK 320.15 -0.93% 2,907,910
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
330.55DKK
Average target price
316.91DKK
Spread / Average Target
-4.13%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NOVO B Stock